Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

PHASE3CompletedINTERVENTIONAL
Enrollment

456

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

September 30, 2009

Conditions
Chronic Heart FailureIron DeficiencyIron Deficiency AnemiaAnaemia
Interventions
DRUG

Ferinject ® (Ferric carboxymaltose)

"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."

DRUG

Normal saline (0.9%)

During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.

Trial Locations (48)

Unknown

Research Sites, Buenos Aires

Research Site, Bad Nauheim

Research Site, Berlin

Research Site, Göttingen

Research Site, Hanover

Research Sites, Heidelberg

Research Site, Herford

Research Site, Herne

Research Site, Kiel

Research Site, München

Research Site, Athens

Research Site, Heraklion

Research Site, Ascoli Piceno

Research Site, Pavia

Research Site, Rome

Research Site, Vicenza

Research Site, Stavanger

Research Site, Bialystok

Research Site, Krakow

Research Site, Opole

Research Site, Piotrkow Trybunalski

Research Site, Siedlce

Research Site, Torun

Research Sites, Warsaw

Research Site, Wałbrzych

Research Site, Wroclaw

Research Site, Włocławek

Research Site, Zabrze

Research Site, Brasov

Research Sites, Bucharest

Reserach Site, Craiova

Research Sites, Târgu Mureş

Reserach Sites, Moscow

Resarch Sites, Saint Petersburg

Research Sites, Veliky Novgorod

Research Site, Alicante

Research Sites, Barcelona

Research Site, Bilbao

Research Site, Madrid

Research Site, Valencia

Research Site, Dnipropetrovsk

Research Site, Donetsk

Research Site, Kharkiv

Research Sites, Kiev

Research Site, Lviv

Research Site, Mykolayiv

Research Site, Odesa

Research Site, Zaporizhzhya

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
lead

Vifor Pharma

INDUSTRY

collaborator

Syneos Health

OTHER

collaborator

ClinStar, LLC

INDUSTRY